About Oritavancin Dosing
The Oritavancin Dose Calculator is a clinical support tool designed to guide healthcare professionals through the preparation and administration of oritavancin (Orbactiv®) for treating adult patients with acute bacterial skin and skin structure infections (ABSSSI). It simplifies the multi-step process from reconstitution to final infusion rate.
Outputs
The calculator provides a comprehensive, step-by-step summary for administering the standard 1200 mg dose, including:
- Reconstitution Plan: The number of vials required and the precise volume of Sterile Water for Injection (SWFI) needed for each.
- Dilution Instructions: The exact volume of reconstituted solution to add to 5% Dextrose Injection (D5W) to achieve the final infusion volume and concentration.
- Administration Rate: The recommended infusion duration (3 hours) and the corresponding calculated infusion rate in mL/hour.
How to Use
Enter the patient's weight and select the appropriate unit (kg or lbs). Click "Calculate" to generate the preparation and administration plan. While the dose for ABSSSI is fixed at 1200 mg for adults, providing the weight allows the tool to display patient-specific context and flag unusually high or low values that may warrant clinical review.
Dosing Overview
For the treatment of ABSSSI in adults, oritavancin is administered as a single 1200 mg dose via intravenous (IV) infusion over 3 hours. A key clinical advantage is that no dose adjustments are required for patients with mild, moderate, or severe renal or hepatic impairment.
Switching
Oritavancin is a single-dose outpatient parenteral antimicrobial therapy (S-OPAT) agent. As a single infusion constitutes a complete course of therapy for ABSSSI, there is no subsequent switching to an oral antibiotic. If a patient is being switched *from* another antibiotic to oritavancin, the timing should be determined by the treating clinician.
Missed Dose
A "missed dose" is not applicable to a single-dose regimen. If the 3-hour infusion is interrupted, it should be resumed as soon as possible to ensure the full 1200 mg dose is delivered. The total infusion time should adhere to institutional protocols for IV line and drug stability.
Safety Alerts
- Heparin Contraindication: Oritavancin artificially prolongs activated partial thromboplastin time (aPTT) for up to 120 hours (5 days). The use of IV unfractionated heparin is contraindicated during this period as aPTT cannot be reliably monitored to ensure safe and effective dosing.
- IV Solution Incompatibility: Oritavancin is incompatible with saline-based solutions, which can cause precipitation. It must ONLY be reconstituted with Sterile Water for Injection (SWFI) and diluted in 5% Dextrose Injection (D5W). Do not mix or co-infuse with other medications.
- Infusion-Related Reactions: Rapid IV infusion can cause reactions similar to "red man syndrome," including flushing of the upper body, urticaria, pruritus, and/or rash. Administering the infusion over the recommended 3-hour period is critical to minimize this risk.
Frequently Asked Questions (FAQ)
Why is the oritavancin dose for ABSSSI fixed at 1200 mg for adults?
Pharmacokinetic and pharmacodynamic (PK/PD) studies have demonstrated that a single 1200 mg dose achieves the necessary target drug exposures to effectively treat ABSSSI across a wide range of adult body weights.
What happens if I accidentally use Normal Saline instead of D5W for dilution?
Using saline-based diluents will cause the drug to precipitate, forming visible particles in the solution. If this occurs, the infusion bag must be discarded immediately and a new dose must be prepared correctly.
Can the 1200 mg dose be administered in less than 3 hours?
No. Administering oritavancin faster than the recommended 3-hour infusion time significantly increases the risk of infusion-related reactions. The slow rate is a critical safety measure.
How long must a patient wait for IV heparin after an oritavancin dose?
IV unfractionated heparin should not be administered for at least 120 hours (5 days) after the oritavancin infusion is complete to avoid dosing errors due to the falsely elevated aPTT.
Why does the preparation require two 600 mg vials?
Oritavancin is supplied by the manufacturer in single-dose vials containing 600 mg of the drug. Therefore, two vials are required to prepare the standard 1200 mg adult dose.
What should the final diluted solution look like?
The final infusion solution should be clear and colorless to pale yellow. Do not use if the solution is cloudy, discolored, or contains particulate matter.
Are there alternatives to heparin if anticoagulation is needed?
Yes, but this requires careful clinical consideration. Anticoagulants that are not monitored using aPTT, such as low-molecular-weight heparins or direct oral anticoagulants (DOACs), may be alternatives. Consult with a pharmacist and institutional guidelines.
References
- ORBACTIV® (oritavancin) Prescribing Information. U.S. Food and Drug Administration. View FDA Label
- Melinta Therapeutics. Orbactiv® (oritavancin) for injection. Official HCP Website
- Stevens DL, Bisno AL, Chambers HF, et al. Practice Guidelines for the Diagnosis and Management of Skin and Soft Tissue Infections: 2014 Update by the Infectious Diseases Society of America. Clin Infect Dis. 2014;59(2):e10-e52. View Guideline
- Saravolatz LD, Stein GE. Oritavancin: a long-half-life lipoglycopeptide. Clin Infect Dis. 2015;61(4):627-632. View on PubMed
I am a Registered Pharmacist under the Pharmacy Act, 1948, and the founder of PharmacyFreak.com. I hold a Bachelor of Pharmacy degree from Rungta College of Pharmaceutical Science and Research. With a strong academic foundation and practical knowledge, I am committed to providing accurate, easy-to-understand content to support pharmacy students and professionals. My aim is to make complex pharmaceutical concepts accessible and useful for real-world application.
Mail- Sachin@pharmacyfreak.com